128 related articles for article (PubMed ID: 36850028)
1. The Importance of Immune Checkpoint Molecule TIGIT in AKI.
Moore KH; Agarwal A
J Am Soc Nephrol; 2023 May; 34(5):725-727. PubMed ID: 36850028
[No Abstract] [Full Text] [Related]
2. Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI.
Noel S; Lee K; Gharaie S; Kurzhagen JT; Pierorazio PM; Arend LJ; Kuchroo VK; Cahan P; Rabb H
J Am Soc Nephrol; 2023 May; 34(5):755-771. PubMed ID: 36747315
[TBL] [Abstract][Full Text] [Related]
3. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
4. [Research Advance of Immune Checkpoint Molecule TIGIT in Hematological Malignancies--Review].
Lu H; Wang HF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):993-997. PubMed ID: 34105506
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
Front Immunol; 2018; 9():2821. PubMed ID: 30555485
[TBL] [Abstract][Full Text] [Related]
6. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
Shaw G; Cavalcante L; Giles FJ; Taylor A
J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
[TBL] [Abstract][Full Text] [Related]
7. Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients.
Li C; Liu H; Duan Z
BMC Immunol; 2024 Feb; 25(1):12. PubMed ID: 38326745
[TBL] [Abstract][Full Text] [Related]
8. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.
Deng C; Li W; Fei Y; Wang L; Chen Y; Zeng X; Zhang F; Li Y
Front Immunol; 2020; 11():1619. PubMed ID: 32793241
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint molecule TIGIT manipulates T cell dysfunction in septic patients.
Sun Y; Ding R; Chang Y; Li J; Ma X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108205. PubMed ID: 34653731
[TBL] [Abstract][Full Text] [Related]
10. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
11. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.
Liu G; Zhang Q; Yang J; Li X; Xian L; Li W; Lin T; Cheng J; Lin Q; Xu X; Li Q; Lin Y; Zhou M; Shen E
Cancer Immunol Immunother; 2022 Feb; 71(2):277-287. PubMed ID: 34129052
[TBL] [Abstract][Full Text] [Related]
12. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
13. TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.
Trivedi P; Jhala G; De George DJ; Chiu C; Selck C; Ge T; Catterall T; Elkerbout L; Boon L; Joller N; Kay TW; Thomas HE; Krishnamurthy B
Front Immunol; 2024; 15():1370907. PubMed ID: 38533515
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
15. Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy.
Meggyes M; Nagy DU; Feik T; Boros A; Polgar B; Szereday L
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142692
[No Abstract] [Full Text] [Related]
16. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
17. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
18. TIGIT immune checkpoint blockade restores CD8
Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
[TBL] [Abstract][Full Text] [Related]
19. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
20. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
